CeriBell, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CeriBell, Inc. (Nasdaq: CBLL) develops and commercializes the Ceribell System, a point-of-care electroencephalography (EEG) platform that combines portable hardware and artificial intelligence-powered algorithms for rapid diagnosis and continuous monitoring of patients at risk of seizures in acute care settings across the United States. The system comprises disposable headbands with ten non-invasive electrodes pre-filled with conductive gel; pocket-sized, battery-operated recorders that capture and wirelessly transmit EEG signals; Clarity, an AI-powered seizure detection algorithm providing real-time alerts for electrographic status epilepticus; and the Ceribell EEG Portal, a cloud-based platform enabling remote access to EEG data, signal quality comparable to conventional EEG, and seizure burden trending for clinicians. Founded in 2014 and headquartered in Sunnyvale, California, the company targets hospitals including ICUs, emergency departments, and VA systems, serving over 615 active accounts as of September 2025 with a focus on improving patient outcomes such as shorter ICU stays and better neurological recovery. Recent developments include its initial public offering in October 2024, raising $180.3 million at $17 per share; FDA 510(k) clearance in November 2025 for the next-generation Clarity algorithm; expanded Clarity clearance for neonates, preterm and up, marking the broadest age range for seizure detection; and FedRAMP high authorization in Q2 2025, unlocking access to nearly 200 VA hospitals; alongside Q3 2025 revenue of $22.6 million, up 31% year-over-year.
Company News
BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL
Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CeriBell Q2 Earnings Call Highlights
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefe
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records
CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
CeriBell Q1 Earnings Call Highlights
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
Ceribell Reports First Quarter 2026 Financial Results